Litcius/Paper detail

A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge

Eric M. Mucker, Joseph W. Golden, Christopher D. Hammerbeck, Jennifer M. Kishimori, Michael Royals, Mathew D. Joselyn, John Ballantyne, Aysegul Nalca, Jay W. Hooper

2021Journal of Virology55 citationsDOIOpen Access PDF

Abstract

The eradication of smallpox and subsequent cessation of vaccination have left a majority of the population susceptible to variola virus or other emerging poxviruses. This is exemplified by human monkeypox, as evidenced by the increase in reported endemic and imported cases over the past decades. Therefore, a malleable vaccine technology that can be mass produced and does not require complex conditions for distribution and storage is sought. Herein, we show that a DNA vaccine, in the absence of a specialized formulation or adjuvant, can protect against a lethal aerosol insult of rabbitpox virus.

Topics & Concepts

VirologyMonkeypoxBiologyVacciniaVirusDNA vaccinationVaccinationVariola virusSmallpoxOrthopoxvirusPopulationSmallpox vaccineSmallpox virusCowpoxImmunityAttenuated vaccinePoxviridaeRNA virusPandemicInfluenza A virusImmunogenicityNucleic acidImmunologyVaccine efficacyInfluenza vaccineNeutralizing antibodyLethal doseOrthomyxoviridaeLive attenuated influenza vaccinePoxvirus research and outbreaksBacillus and Francisella bacterial researchViral Infections and Outbreaks Research